keyword
https://read.qxmd.com/read/38545096/risk-factors-for-graft-versus-host-disease-after-donor-lymphocyte-infusion-following-t-cell-depleted-allogeneic-stem-cell-transplantation
#1
JOURNAL ARTICLE
Eva A S Koster, Peter A von dem Borne, Peter van Balen, Erik W A Marijt, Jennifer M L Tjon, Tjeerd J F Snijders, Daniëlle van Lammeren, Hendrik Veelken, J H Frederik Falkenburg, Constantijn J M Halkes, Liesbeth C de Wreede
INTRODUCTION: Unmodified donor lymphocyte infusions (DLI) after allogeneic stem cell transplantation (alloSCT) can boost the beneficial Graft-versus-Leukemia (GvL) effect but may also induce severe Graft-versus-Host-Disease (GvHD). To improve the balance between GvL and GvHD, it is crucial to identify factors that influence the alloreactivity of DLI. METHODS: We investigated the effects of the presence of patient-derived antigen-presenting cells at time of DLI as estimated by the bone marrow (BM) chimerism status, lymphopenia as measured by the absolute lymphocyte count (ALC) at time of DLI, and the presence of a viral infection ( de novo or reactivation) close to DLI on the risk of GvHD after DLI...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38543824/torque-teno-virus-dna-load-in-blood-as-an-immune-status-biomarker-in-adult-hematological-patients-the-state-of-the-art-and-future-prospects
#2
REVIEW
Eliseo Albert, Estela Giménez, Rafael Hernani, José Luis Piñana, Carlos Solano, David Navarro
A solid body of scientific evidence supports the assumption that Torque teno virus (TTV) DNA load in the blood compartment may behave as a biomarker of immunosuppression in solid organ transplant recipients; in this clinical setting, high or increasing TTV DNA levels precede the occurrence of infectious complications, whereas the opposite anticipates the development of acute rejection. The potential clinical value of the TTV DNA load in blood to infer the risk of opportunistic viral infection or immune-related (i...
March 17, 2024: Viruses
https://read.qxmd.com/read/38543084/graft-versus-host-disease-can-biomarkers-assist-in-differential-diagnosis-prognosis-and-therapeutic-strategy
#3
REVIEW
Vaia-Aikaterini Alexoudi, Eleni Gavriilaki, Angeliki Cheva, Ioanna Sakellari, Stavroula Papadopoulou, Konstantinos Paraskevopoulos, Konstantinos Vahtsevanos
A crucial complication after allogeneic hematopoietic cell transplantation (alloHCT), namely, acute graft-versus-host disease (aGVHD), occurs in about 50% of transplant recipients, leading to high morbidity and mortality. Thus far, the diagnosis of GVHD has been mainly established through clinical features and histologic or laboratory evidence of periductal lymphocyte infiltration, fibroplasia, and mixed lymphocytic and plasmocytic inflammation. Intensive research is focused on identifying biomarkers for the early diagnosis, prediction of disease, response to treatment, prognosis, and risk stratification of patients...
February 26, 2024: Pharmaceuticals
https://read.qxmd.com/read/38538977/comparison-of-rabbit-atlg-and-atg-for-gvhd-prophylaxis-in-hematological-malignancies-with-haploidentical-hematopoietic-stem-cell-transplantation
#4
JOURNAL ARTICLE
Zhengqin Tian, Qihang Man, Yixin Yang, Hexian Guan, Ying Wang, Rongmu Luo, Jingbo Wang
Rabbit anti-human T lymphocyte globulin (ATLG) and anti-thymocyte globulin (ATG) are commonly used for graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (HSCT). Yet, their efficacy and safety have seldom been compared in hematological malignancies with haploidentical HSCT. A retrospective analysis with 28 ATLG (total dosage, 20-30 mg/kg) and 18 ATG (total dosage, 8-10 mg/kg) patients were performed. The cumulative incidences of chronic GVHD and relapse were comparable between both groups...
March 28, 2024: Annals of Hematology
https://read.qxmd.com/read/38538862/atg-or-post-transplant-cyclophosphamide-to-prevent-gvhd-in-matched-unrelated-stem-cell-transplantation
#5
JOURNAL ARTICLE
Olaf Penack, Mouad Abouqateb, Christophe Peczynski, William Boreland, Nicolaus Kröger, Matthias Stelljes, Tobias Gedde-Dahl, Igor Wolfgang Blau, Thomas Schroeder, Urpu Salmenniemi, Alexander Kulagin, Régis Peffault de Latour, Stephan Mielke, Robert Zeiser, Ivan Moiseev, Hélène Schoemans, Christian Koenecke, Zinaida Peric
There is a high risk of GVHD and non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) from unrelated donors. Prophylaxis with rabbit anti-thymocyte globulin (rATG) is standard in Europe but post-transplantation Cyclophosphamide (PTCy) is an emerging alternative. We analyzed outcomes of rATG (n = 7725) vs. PTCy (n = 1039) prophylaxis in adult patients with hematologic malignancies undergoing peripheral blood alloSCT from 10/10 antigen-matched unrelated donors (MUD) between January 2018 and June 2021 in the EBMT database...
March 27, 2024: Leukemia
https://read.qxmd.com/read/38537062/late-cytomegalovirus-disease-after-hematopoietic-cell-transplantation-significance-of-novel-transplantation-techniques
#6
JOURNAL ARTICLE
Alicja Sadowska-Klasa, Sezen Özkök, Hu Xie, Wendy M Leisenring, Danniel Zamora, Sachiko Seo, Jordan Sheldon, Stephanie J Lee, Keith R Jerome, Margaret L Green, Michael J Boeckh
Pre-emptive therapy (PET) and letermovir prophylaxis are effective in preventing CMV disease within the first 100 days after allogeneic hematopoietic cell transplantation (HCT) but are associated with late-onset CMV disease. We retrospectively examined the clinical manifestations, risk factors, prevention algorithm, and outcome of late CMV disease in CMV seropositive day 100 survivors transplanted between 2001-2017 (PET cohort) and 2018-2021 (letermovir cohort). There were 187 episodes of late CMV disease among 2469 day 100 survivors and the estimated cumulative incidence of first late CMV disease was 6...
March 27, 2024: Blood Advances
https://read.qxmd.com/read/38534926/haploidentical-hematopoietic-stem-cell-transplantation-for-patients-with-severe-aplastic-anemia-single-centre-experience
#7
Vered Stavi, Niranjan Khaire, Jeffrey H Lipton, Rajat Kumar
Severe aplastic anemia (SAA) is a life-threatening type of aplastic anemia for which allogeneic stem cell transplantation or immunosuppressive therapy are the principal treatment modalities. Only about 25-30% of patients have a matched sibling donor, and finding an unrelated donor in ethnic minorities is a challenge. The use of related haploidentical donor transplants in severe aplastic anemia is uncommon. We would like to report our experience with the first four patients who underwent haploidentical transplants for severe aplastic anemia...
February 26, 2024: Current Oncology
https://read.qxmd.com/read/38532599/high-sensitivity-of-host-helios-neuropilin-1-treg-to-pretransplant-conditioning-hampers-development-of-ox40-bright-integrin-%C3%AE-7-regulatory-cells-in-acute-gastrointestinal-gvhd
#8
JOURNAL ARTICLE
Nikolett Lupsa, Barbara Érsek, Csenge Böröczky, Dávid Kis, Eszter Szarka, Katalin Lumniczky, Géza Sáfrány, Zoltán S Zádori, Árpád Szöőr, Edit I Buzás, Zoltán Pós
This study sought to compare the behavior of Treg subsets displaying different coexpression patterns of Neuropilin-1 (Nrp1) and Helios, under the influence of gut stress unrelated to hematopoietic stem cell transplantation, pretransplantation conditioning, and posttransplant gastrointestinal acute graft versus host disease (GI-aGvHD). Host CD4+ /CD25hi /Foxp3+ Treg cells, identified by flow cytometry, were isolated from various tissues of mice affected by these stressors. Expression of CD25, CTLA-4, CD39, OX40, integrin-β7, LAG3, TGFβ/LAP, granzyme-A, -B, and interleukin-10 was compared in four Treg subsets displaying Helios or Nrp1 only, both or none...
March 26, 2024: European Journal of Immunology
https://read.qxmd.com/read/38527842/-safety-and-efficacy-of-donor-derived-chimeric-antigen-receptor-t-cell-therapy-in-patients-with-relapsed-b-cell-acute-lymphoblastic-leukemia-after-allogeneic-hematopoietic-stem-cell-transplantation
#9
JOURNAL ARTICLE
Y Q Zhuo, S F Tu, X Zhou, J L Yang, L J Zhou, R Huang, Y X Huang, M F Li, B Jin, B Wang, S Q Li, Z T Yuan, L H Zhang, L Liu, S B Wang, Y H Li
Objective: To investigated the safety and efficacy of donor-derived CD19+ or sequential CD19+ CD22+ chimeric antigen receptor T-cell (CAR-T) therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: The data of 22 patients with B-ALL who relapsed after allo-HSCT and who underwent donor-derived CAR-T therapy at the Zhujiang Hospital of Southern Medical University and the 920th Hospital of Joint Logistics Support Force of the People's Liberation Army of China from September 2015 to December 2022 were retrospectively analyzed...
January 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38527841/-single-non-blood-related-umbilical-cord-blood-transplantation-using-a-reduced-intensity-conditioning-regimen-for-the-treatment-of-severe-aplastic-anemia
#10
JOURNAL ARTICLE
Y Wu, B L Tang, K D Song, G Y Sun, T Z Pan, A J Huang, B B Yan, X Y Zhu
Objective: To evaluated the clinical efficacy of a reduced-intensity preconditioning regimen for single non-blood-related umbilical cord blood transplantation (sUCBT) in the treatment of severe aplastic anemia (SAA) . Methods: The clinical data of 63 patients with SAA who underwent sUCBT from January 2021 to July 2023 at the Department of Hematology of the First Affiliated Hospital of USTC were retrospectively analyzed. Fifty-two patients received total body irradiation/total bone marrow irradiation (TMI) combined with fludarabine or a cyclophosphamide- conditioning regimen (non-rATG group) , while 11 patients received rabbit anti-human thymocyte immunoglobulin (rATG) combined with TMI, fludarabine, or the cyclophosphamide-conditioning regimen (rATG group) ...
January 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38527839/-evaluation-of-differences-in-quality-of-life-in-patients-with-chronic-graft-versus-host-disease
#11
JOURNAL ARTICLE
S Q Huang, R H Huang, Y Quan, F M Wang, X J Cheng, X Q Wang, X Zhang
Objective: To evaluate the status of, differences in, and factors influencing quality of life (QoL) in patients with chronic graft-versus-host disease (GVHD). Methods: From September 2021 to February 2023, a cross-sectional study of 140 patients with chronic GVHD was conducted at our center. Symptom burden was assessed by the Lee Symptomatology Scale (LSS), and QoL was assessed by the Medical Outcome Study 36-Item Short-Form Health Survey (SF-36) (version 1) and five-level EuroQoL five-dimensional questionnaire (EQ-5D-5L)...
January 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38527835/-clinical-analysis-of-14-patients-aged-%C3%A2-50-years-with-high-risk-multiple-myeloma-treated-with-allogeneic-hematopoietic-stem-cell-transplantation
#12
JOURNAL ARTICLE
P Pan, J L Wang, W H Zhai, Q L Ma, D L Yang, S Z Feng, M Z Han, A M Pang, E L Jiang
Objective: To evaluate the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in young patients with high-risk multiple myeloma (HRMM) and analyzed the factors affecting patient prognosis. Methods: In this retrospective study, we analyzed the clinical data of 14 patients with HRMM with cytogenetic abnormalities or high-risk biological factors who underwent allo-HSCT at the Hematopoietic Stem Cell Transplantation Center of the Institute of Hematology & Blood Diseases Hospital between November 2016 and November 2022...
January 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38527372/correction-to-microbiota-predict-infections-and-acute-graft-versus-host-disease-after-pediatric-allogeneic-hematopoietic-stem-cell-transplantation
#13
(no author information available yet)
No abstract text is available yet for this article.
March 25, 2024: Journal of Infectious Diseases
https://read.qxmd.com/read/38522856/severe-liver-dysfunction-after-donor-lymphocyte-infusion-for-relapsed-multiple-myeloma
#14
Tae-Hoon No, Nae-Yun Heo, Seung Ha Park, Joon Hyuk Choi, Junghwan Lee, Sung Nam Lim, Seon Yang Park
Donor lymphocyte infusion (DLI) is performed to augment an anti-tumor immune response or ensure donor stem cells remain engrafted following allogeneic stem cell transplantation but may induce graft-versus-host disease (GVHD) involving skin, intestine, and liver. Although hepatic involvement of GVHD can manifest as mild to severe hepatitis, few reports have mentioned acute severe liver dysfunction with encephalopathy. We experienced a case of acute severe liver dysfunction with semicoma after DLI in a patient with relapsed multiple myeloma following allogeneic stem cell transplantation, in whom chronic viral hepatitis B had been suppressed by antiviral treatment...
March 25, 2024: Korean Journal of Gastroenterology, Taehan Sohwagi Hakhoe Chi
https://read.qxmd.com/read/38522578/the-role-of-molecular-or-cytogenetic-response-as-a-favorable-prognostic-factor-before-hematopoietic-stem-cell-transplantation-for-chronic-myeloid-leukemia
#15
JOURNAL ARTICLE
Giuliana Rosendo de Oliveira Medeiros, Vaneuza Araújo Moreira Funke, Alberto Cardoso Martins Lima, Ana Lúcia Vieira Mion, Isabela Menezes, Daniela Carinhanha Setubal, Caroline Bonamin Dos Santos Sola, Gláucia Tagliari, Rafael Marchesini, Samir Kanaan Nabhan, Ricardo Pasquini
Tyrosine kinase inhibitors (TKIs) have revolutionized therapy for patients with chronic myeloid leukemia (CML) over the last two decades. However, some patients still do not achieve an adequate response to these drugs, and hematopoietic stem cell transplantation (HSCT) is indicated in this scenario. We present the results of a 20-year follow-up study of 70 patients who underwent transplantation after TKI failure. The primary objective of the study was to evaluate overall survival (OS) and the secondary objective was to evaluate the outcomes of relapse-free survival (RFS), GVHD-free, relapse-free survival (GFRS) and the incidences of relapse (RI), non-relapse mortality (NRM), acute and chronic GVHD...
March 22, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38520720/significant-impact-of-antibiotic-exposure-on-gi-gvhd-nrm-and-grfs-following-allogeneic-hct-with-non-myeloablative-flu-tbi-conditioning
#16
JOURNAL ARTICLE
Lenneke F J van Groningen, Suzanne van Dorp, Manita E J Bremmers, Shahira Fazel, Mieke W H Roeven, Nicole M A Blijlevens, Walter J F M van der Velden
BACKGROUND: Acute gastro-intestinal graft- versus -host disease (GI-GVHD) and non-relapse mortality (NRM) after allogeneic HCT are closely related to loss of microbial diversity and intestinal dominance by single taxa resulting from the use of antibiotics, dietary changes, and mucosal barrier injury. There is a paucity of data on the impact of use of antibiotics in HCT after Flu-TBI-based non-myeloablative (NMA) conditioning where there is absence of mucositis and limited malnutrition...
March 23, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38517664/diagnostic-prediction-of-gastrointestinal-graft-versus-host-disease-based-on-a-clinical-ct-signs-nomogram-model
#17
JOURNAL ARTICLE
Qing Feng, Fengming Xu, Kaiming Guan, Tao Li, Jing Sheng, Wei Zhong, Haohua Wu, Bing Li, Peng Peng
OBJECTIVE: Gastrointestinal graft-versus-host disease (GI-GVHD) is one of the complications that can easily occur after hematopoietic stem cell transplantation (HSCT). Timely diagnosis and treatment are pivotal factors that greatly influence the prognosis of patients. However, the current diagnostic method lacks adequate non-invasive diagnostic tools. METHODS: A total of 190 patients who suspected GI-GVHD were retrospectively included and divided into training set (n = 114) and testing set (n = 76) according to their discharge time...
March 22, 2024: Insights Into Imaging
https://read.qxmd.com/read/38517548/secondary-solid-malignancies-and-precancerous-lesions-after-allogeneic-hematopoietic-stem-cell-transplantation-using-non-total-body-irradiation-based-conditioning-in-acute-myeloid-leukemia
#18
JOURNAL ARTICLE
Gruber Isabella, Appel Katharina, Edinger Matthias, Koelbl Oliver, Wolff Daniel
INTRODUCTION: Long-term survivors have an increased risk of developing secondary solid malignancies (SSMs) after allogeneic-hematopoietic stem cell transplantation (allo-HSCT) with graft-versus-host disease (GVHD) potentially modulating these risks. METHODS: This retrospective study analyzed the cumulative incidences of SSMs after chemotherapy-based conditioning for allo-HSCT patients with acute myeloid leukemia (n = 266) transplanted at the University Hospital Regensburg between 1999 and 2016...
March 22, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38511425/transplant-versus-no-transplant-in-myelodysplastic-syndrome-and-acute-myeloid-leukemia-with-tp53-mutation-a-referral-center-experience
#19
JOURNAL ARTICLE
Kittika Poonsombudlert, Sarah Mott, Benda Miller, Prajwal Dhakal, Anthony Snow, Sarah Hornberg, Ratdanai Yodsuwan, Christopher Strouse, Hira Shaikh, Margarida Magalhaes-Silverman, Grerk Sutamtewagul
A remarkably high rate of post-transplant relapse in patients with TP53-mutated myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) calls to question the utility of allogeneic stem cell transplant (HSCT). We, therefore, performed a retrospective analysis to compare the outcomes between HSCT (N = 38) versus non-HSCT (N = 45) approaches. Patients in the HSCT cohort were younger (median age 63 vs. 72) while patients in the non-HSCT cohort more commonly had complex karyotype with chromosome 17 aberrancy and 5q deletion (p < ...
March 21, 2024: European Journal of Haematology
https://read.qxmd.com/read/38509104/association-between-oral-and-fecal-microbiome-dysbiosis-and-treatment-complications-in-pediatric-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplantation
#20
JOURNAL ARTICLE
M Faraci, C Bonaretti, G Dell'Orso, F Pierri, S Giardino, F Angiero, S Blasi, G Farronato, E Di Marco, A Trevisiol, E Olcese, L Rufino, M Squillario, R Biassoni
The oral and gastrointestinal mucosae represent the main targets of the toxic effect of chemo and/or radiotherapy administered during the conditioning regimen before hematopoietic stem cell transplant (HSCT). These harmful consequences and the immunological complications that may occur after the transplant (such as Graft versus Host Disease, GvHD) are responsible for the clinical symptoms associated with mucositis during the aplasia phase, like pain, nausea, vomiting, and diarrhea. These toxicities could play a critical role in the oral and gastrointestinal microbiomes during the post-transplant phase, and the degree of microbial dysbiosis and dysregulation among different bacterial species could also be crucial in intestinal mucosa homeostasis, altering the host's innate and adaptive immune responses and favoring abnormal immune responses responsible for the occurrence of GvHD...
March 20, 2024: Scientific Reports
keyword
keyword
59453
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.